Meeting
2022 ASCO Annual Meeting
PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 < 50%: A multiomics approach.
Authors
Marina Chiara Garassino
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Marina Chiara Garassino , Claudia Proto , James M Dolezal , Arsela Prelaj , Luca Agnelli , Tiziana Triulzi , Alessandra Fabbri , Roberto Ferrara , Francesco Sgambelluri , Tommaso Torelli , Silvia Brich , Sara Manglaviti , Andrea Anichini , Roberta Mortarini , Giorgio Trinchieri , Giancarlo Pruneri , Filippo G. De Braud , Valter Torri , Monica Ganzinelli , Giuseppe Lo Russo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NTC03447678
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9051)
DOI
10.1200/JCO.2022.40.16_suppl.9051
Abstract #
9051
Poster Bd #
39
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
PEOPLE (NTC03447678), a phase II trial of first-line, single-agent pembrolizumab in advanced NSCLC with low PD-L1: Clinical outcomes and association with circulating immune biomarkers.
First Author: Giuseppe Lo Russo
Poster
2022 ASCO Annual Meeting
Sintilimab versus pembrolizumab in monotherapy or combination with chemotherapy as first-line therapy for advanced non–small cell lung cancer: Results from phase 2, randomized clinical trial (CTONG1901).
First Author: Si-Yang Maggie Liu
Poster
2023 ASCO Annual Meeting
Phase 2 trial of epidermal growth factor (EGF) vaccine CIMAvax in combination with pembrolizumab in first line and maintenance setting in advanced non–small cell lung cancer patients.
First Author: Prantesh Jain
Poster
2023 ASCO Annual Meeting
Real-world outcomes of first-line immune checkpoint inhibitors with or without chemotherapy in KRAS G12C altered NSCLC according to PD-L1 status.
First Author: Charu Aggarwal